Optiscan soars on new InVue imaging device for precision surgery
Posted: 27 June 2024 Optiscan is excited to be included in Stockhead regarding the unveiling of InVue™ – our next gen microscopic medical imaging device for precision surgery. The article focuses on how InVue™ broadens Optiscan’s product portfolio in the surgical…
MTPConnect strengthens life science links with US through MoU with Biocom California at the 2024 BIO Convention
Posted: 27 June 2024 MTPConnect, Australia’s life sciences innovation accelerator, and Biocom California have committed to working closely together to support the growth of life sciences companies, with the signing today of a Memorandum of Understanding at the 2024…
MTPConnect Workforce Initiative Delivers Skills Needed to Power Life Sciences Sector Growth
Posted: 27 June 2024 Over the last three and a half years, REDI has delivered training, mentoring and industry placements to more than 8,400 participants across Australia, nearly double the original target. The report – ‘Improving workforce skills in…
Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation
Posted: 27 June 2024 Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million). This new fund will…
New test promises earlier detection of dementia onset
Posted: 27 June 2024 A new test promises to predict whether someone will get dementia, almost a decade before diagnosis. An international research team, including Associate Professor Adeel Razi, from Melbourne’s Monash University, have developed a new method…
A promising vaccine approach to induce longer-lasting protective immunity against COVID-19
Posted: 27 June 2024 A scientific team from the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine) and Monash University has engineered a COVID-19 vaccine that induced – in pre-clinical models –…
One-two punch treatment delivers blood cancer knockout
Posted: 27 June 2024 A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancers. A new study by WEHI…
Clinical trials are a critical step in the research and development process for new drugs, vaccines, medical devices and diagnostics.
Posted: 27 June 2024 Participants in clinical trials get early access to these potentially life-saving new therapies, while at the same time advancing medical knowledge. More broadly, clinical trial activity contributes to the development of a thriving research…
BioMelbourne Network Board strengthened with five new appointments
Posted: 1 July 2024 BioMelbourne Network, the peak body in the Victorian healthtech industry, is pleased to announce the appointment of five new Directors and Treasurer to its Board, effective from 1 July 2024. These appointments refill the…
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
Posted: 27 July 2024 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk…
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer
Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces topline results from the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial…
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company…
